International Stem Cell Corporation

ISCOOTC · Healthcare · Biotechnology

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in North America,…

––

报价 2026-03-04

市值

–

PE (TTM)

–

预期 PE (FY2026)

–

52 周区间

–

筛选结果

live estimate

Filter✗ 高增长✗ Cheap✗ GARP

excluded industry: Biotechnology

研究结论

还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16

公司	市值	今日	预期营收增速	毛利率	PE	EV/EBITDA	P/FCF
ISCOInternational Stem Cell Corporation	–	–	–	–	–	–	–
EVFMEvofem Biosciences, Inc.	–	–	–	–	–	–	–
MRZMMarizyme, Inc.	–	–	–	–	–	–	–
NSTMNovelStem International Corp.	–	–	–	–	–	–	–
DTRKDATATRAK International, Inc.	–	–	–	–	–	–	–
VCNXVaccinex, Inc.	–	–	–	–	–	–	–
同行中位数	–	–	–	–	–	–	–

研究全文

L2 基本面 memo

尚无基本面 memo

点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

暂无季度数据（首次研究运行后填充）。

研究材料

Filing 摘要

10-Q · 2026-05-140001193125-26-223926 10-K · 2026-03-300001193125-26-131723

电话会纪要摘要

暂无纪要摘要。

我的笔记

AI 刷新不会修改

判断与复查· 可选：填复查日期后会进首页待办

加载中…

关键指标

其他估值

EV/EBITDA–

P/FCF–

P/S–

MC/GP–

PB–

PEG–

经营

营收 (TTM)–

营收同比 (TTM)–

净利润 (TTM)–

净利同比 (TTM)–

下一财年营收增速-2.1%

毛利率–

经营利润率–

净利率–

FCF (TTM)–

ROE–

ROIC–

资产负债

负债/权益–

流动比率–

Beta–

分析师

EPS 超预期近 4 季 1 次 beat

+33.3

+0.0

2012-112014-11

内部人交易

近 180 天 · 仅公开市场买卖

买入 0 笔

卖出 1 笔

$10,497

净额

−$10,497

公司资料

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in North America, Asia, Europe, and internationally. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; and develops, manufactures, and markets anti-aging skincare and human cell culture products. The company's human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

展开全文

CEO Andrey Semechkin

员工 32

IPO 2007-05-01

官网 StockAnalysis